HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Olanzapine-induced parkinsonism associated with smoking cessation.

AbstractPURPOSE:
The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.
SUMMARY:
A 73-year-old Caucasian woman with a recent diagnosis of Parkinson disease and a history of chronic obstructive pulmonary disease, hyperlipidemia, chronic osteoarthritis, and hypothyroidism was hospitalized for altered mental status, weakness, and ambulatory dysfunction. The diagnosis of Parkinson disease was made approximately four months prior. Despite initiation of carbidopa-levodopa, the patient's symptoms did not improve, and her mental and physical status declined. The patient was taking olanzapine 30 mg daily for bipolar disorder and had a 40-pack-year history of smoking, but she quit smoking approximately four months before this hospitalization. The results of a neurologic evaluation suggested that the patient did not have Parkinson disease but was possibly experiencing olanzapine toxicity secondary to smoking cessation. Carbidopa-levodopa was discontinued. Psychiatry was consulted, and a monthlong cross-taper to discontinue olanzapine and initiate aripiprazole with a target dosage of 20 mg daily was recommended. During the course of therapy, the patient's level of alertness and bradykinesia improved. Overall, it was noted that her extrapyramidal symptoms were gradually improving; two days before hospital discharge, she was noted to have no definite remaining evidence of parkinsonism. In this case, use of the Naranjo et al. adverse-drug-reaction probability scale and the drug interaction probability scale indicated that the adverse effects were probably related to the interaction between smoking and olanzapine.
CONCLUSION:
A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.
AuthorsJennifer Arnoldi, Nicole Repking
JournalAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (Am J Health Syst Pharm) Vol. 68 Issue 5 Pg. 399-401 (Mar 01 2011) ISSN: 1535-2900 [Electronic] England
PMID21330680 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antipsychotic Agents
  • Benzodiazepines
  • Olanzapine
Topics
  • Aged
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Benzodiazepines (adverse effects, therapeutic use)
  • Bipolar Disorder (drug therapy)
  • Drug Interactions
  • Female
  • Humans
  • Olanzapine
  • Parkinsonian Disorders (chemically induced)
  • Smoking (adverse effects)
  • Smoking Cessation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: